IDEXX Laboratories, Inc. (NASDAQ:IDXX) is Westwind Capital's 10th Largest Position

Westwind Capital lifted its holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 2.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,836 shares of the company's stock after acquiring an additional 1,174 shares during the quarter. IDEXX Laboratories accounts for 4.8% of Westwind Capital's holdings, making the stock its 10th biggest position. Westwind Capital owned approximately 0.06% of IDEXX Laboratories worth $19,249,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Hurley Capital LLC purchased a new position in IDEXX Laboratories during the fourth quarter worth about $29,000. Rialto Wealth Management LLC acquired a new stake in IDEXX Laboratories during the 4th quarter worth $30,000. Colonial Trust Co SC raised its position in IDEXX Laboratories by 84.8% during the 4th quarter. Colonial Trust Co SC now owns 85 shares of the company's stock worth $35,000 after buying an additional 39 shares during the last quarter. Itau Unibanco Holding S.A. increased its holdings in shares of IDEXX Laboratories by 540.0% in the 4th quarter. Itau Unibanco Holding S.A. now owns 96 shares of the company's stock valued at $40,000 after purchasing an additional 81 shares in the last quarter. Finally, Retirement Wealth Solutions LLC grew its stake in IDEXX Laboratories by 40.0% in the 1st quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company's stock valued at $44,000 after acquiring an additional 30 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company's stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total value of $645,548.40. Following the transaction, the director now owns 1,801 shares in the company, valued at approximately $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Insiders own 0.98% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on the stock. Morgan Stanley lifted their price target on shares of IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Stifel Nicolaus raised their target price on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research report on Monday, May 19th. Wall Street Zen lowered shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Finally, Leerink Partners lifted their price objective on shares of IDEXX Laboratories from $515.00 to $580.00 and gave the company an "outperform" rating in a research note on Wednesday, June 11th. Four research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $546.00.

IDEXX Laboratories Stock Up 0.7%

IDEXX Laboratories stock opened at $531.32 on Friday. The company has a 50-day simple moving average of $499.01 and a 200-day simple moving average of $450.75. The firm has a market capitalization of $42.73 billion, a P/E ratio of 49.11, a P/E/G ratio of 3.85 and a beta of 1.55. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.81 and a current ratio of 1.16. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $535.20.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a net margin of 22.76% and a return on equity of 57.35%. The company had revenue of $998.43 million during the quarter, compared to the consensus estimate of $998.25 million. During the same period in the prior year, the company earned $2.71 EPS. IDEXX Laboratories's revenue was up 3.6% on a year-over-year basis. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.